| COVID-19 | coronavirus disease 2019 |
| SARS | severe acute respiratory syndrome |
| SARS-CoV-2 | severe acute respiratory syndrome coronavirus-2 |
| PHEIC | public health emergency of international concern |
| S-protein | spike glycoprotein |
| ACE2 | angiotensin-converting enzyme 2 |
| ACE | angiotensin-converting enzyme |
| RBD | receptor-binding domain |
| cryo-EM | cryo-electron microscopy |
| RAS | renin-angiotensin system |
| Ang I | angiotensin I |
| Ang II | angiotensin II |
| AT1 | angiotensin receptor type 1 |
| AT2 | angiotensin receptor type 2 |
| ACEIs | ACE inhibitors |
| ARBs | AT1 receptor blockers |
| ARDS | acute respiratory distress syndrome |
| ICU | intensive care unit |
| ADAM-17 | ADAM metallopeptidase domain 17 |
| TMPRSS2 | Transmembrane Serine Protease 2 |
| AR | androgen receptor |
| DHT | dihydrotestosterone |
| LNCaP | activin-sensitive prostate cancer cells |
| ER | endoplasmic reticulum |
| hESC | human embryonic stem cell |
| PD | peptidase domain |
| NAAE | N-(2-aminoethyl)-1 aziridine-ethanamine |
| IC50 | the half maximal inhibitory concentration |
| KD | the calculated affinity |
| IFN | interferon |
| IL | interleukin |
| ERK | extracellular signal-regulated kinase |
| JNK | c-Jun N-terminal kinase |
| IPF | idiopathic pulmonary fibrosis |
| PAH | pulmonary arterial hypertension |
| ALI | acute lung injury |
| LPS | lipopolysaccharide |
| TLR4 | toll-like receptor 4 |
| MAP | mitogen-activated protein |
| ERK/MAPK | extracellular-signal-regulated kinase/mitogen-activated protein kinase |
| NF-κB | nuclear factor-κB |
| AMPA | alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid |
| APJ | the apelin receptor |
| SIRT1 | Sirtuin 1 |
| AMPK | AMP-activated protein kinase |
| T2DM | Type 2 diabetes mellitus |
| ISG | interferon stimulated gene |
| fMLP | N-formylmethionyl-leucyl-phenylalanine |
| MAS1 | the G protein-coupled receptor Mas |